Welcome!

News Feed Item

MELA Sciences Announces the Results of its Third Clinical Advisory Meeting and the Four Clinical Posters Presented at the Winter Clinical Dermatology Conference

MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced the results of its third company-sponsored Clinical Advisory meeting hosted during the Winter Clinical Dermatology Conference in Hawaii where technical advancements of MelaFind® and future technology development opportunities were discussed and user’s validated its clinical use. MELA Sciences also displayed four clinical posters presentations at the conference, which took place from January 17 – 22, 2014.

The poster presentations reviewed clinical data derived from practice and clinical settings that highlighted how MelaFind has helped dermatologists in the assessment of clinically ambiguous pigmented skin lesions in various patients including young adults, an area of growing concern, and those with atypical mole syndrome. To view the posters and their accompanying abstract please click here.

The poster authored by Dr. Darrell Rigel, titled Physical Properties, Novel Features and Clinical Validation of a Multispectral Digital Skin Lesion Analysis Device for Melanoma, and outlined below was named Poster of the Day on the first day of the conference.

Highlights of the studies and the data shown in the poster presentations are as follows:

Physical Properties, Novel Features and Clinical Validation of a Multispectral Digital Skin Lesion Analysis Device (MSDSLA) for Melanoma Detection - Darrell S. Rigel, MD, MS NYU School of Medicine, New York, NY; Laura Ferris, MD, PhD, University of Pittsburgh. Pittsburgh, PA; Arthur Sober, MD, Harvard University, Boston, MA; Clay J. Cockerell, MD, University of Texas Southwestern, Dallas, TX

  • Retrospective data from the MelaFind pivotal study was used to investigate the MelaFind multispectral images and classifier score result as a tool to differentiate cutaneous melanoma from other pigments skin lesions.
  • Results showed the average classifier scores of melanomas, high-grade lesions, non-melanoma skin cancers, and histologically benign nevi were 3.5, 2.7, 2.6 and 1.6 respectively.
  • Further results showed an increase in the mean classifier score result with each additional clinical characteristic present in the lesion.

Assessing the Predictive Probability of Melanoma and Other High Risk Pigmented Lesions Using Data Provided by a Multispectral digital Skin Lesion Analysis Device - Jane Yoo, MD, MPP, Dept. of Dermatology, Albert Einstein School of Medicine, Bronx, NY; Natalie Tucker, BS, MELA Sciences, Irvington, NY; Darrell S. Rigel, MD, MS, Dept. of Dermatology, NYU School of Medicine, NYC, NY

  • A risk prediction model was built to assess the predictive probability of melanoma or a high-risk lesion for consideration for biopsy based on data obtained from MelaFind.
  • Results show a potential quantitative predictive capacity for presence of melanoma and other high risk pigmented lesions using the MelaFind device.

In addition to presenting data from the four studies, MELA Sciences held its third Clinical Advisory Meeting for current and prospective MelaFind users and thought leaders. In attendance was Dr. Antonanella Calame, dermatologist, dermatopathologist and medical director of Compass Dermatology and Dermatopathology in La Jolla, CA. Dr. Calame, a user of MelaFind, said, “As dermatologists, one of our most important goals is diagnosing melanoma, the deadliest form of skin cancer, at its earliest and most curable stage. The MelaFind system’s images and data analysis tools help dermatologists with one of the most challenging questions we face each day when evaluating clinically ambiguous pigments skin lesions: “Is this lesion atypical enough for me to remove and investigate further via histology?” MelaFind’s analysis of a lesion’s architectural structure gives us access to new information deeper into the skin, where the human eye cannot see, and helps us answer this critical question, improving overall outcomes for both patient and clinician. These tools are available for the first time in medicine and MelaFind is just the beginning. If patient outcomes are our foremost concern, adoption of such technologies should be widespread and soon become part of the standard of care.”

The Winter Clinical Dermatology Conference was conducted over four days and had nearly 400 participants from various fields of dermatology, medical and cosmetic. In discussing the Advances in the Diagnosis of Melanoma, Dr. Laura Ferris credited MelaFind as an important instrument in helping to detect melanoma.

Please follow us:

         

 

Twitter:

@MELASciencesIR or @MelaFind

 

StockTwits:

@MELASciencesIR

 

Facebook:

www.facebook.com/MelaFind

About MELA Sciences, Inc. www.melasciences.com

MELA Sciences is a medical device company developing dermatology diagnostics utilizing state-of-the-art optical imaging. The flagship product is MelaFind®, an FDA, PMA and CE Mark approved, non-invasive diagnostic tool to aid dermatologists in melanoma evaluation and diagnosis. MelaFind® uses a variety of visible to near-infrared light waves to evaluate skin lesions from the surface to 2.5 mm beneath the skin. It provides images and data on the relative disorganization of a lesion's structure that provides substantial additional perspective to aid melanoma diagnosis. MELA is also exploring new potential uses for its core imaging technology and algorithms.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and may contain words such as “seeks,” “look forward,” and “there seems” that suggest future events or trends. These statements are based on our current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from our expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all of these forward-looking statements may prove to be incorrect or unreliable. MELA Sciences assumes no duty to update its forward-looking statements and urges investors to carefully review its SEC disclosures available at www.sec.gov and www.melasciences.com.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
What's the role of an IT self-service portal when you get to continuous delivery and Infrastructure as Code? This general session showed how to create the continuous delivery culture and eight accelerators for leading the change. Don Demcsak is a DevOps and Cloud Native Modernization Principal for Dell EMC based out of New Jersey. He is a former, long time, Microsoft Most Valuable Professional, specializing in building and architecting Application Delivery Pipelines for hybrid legacy, and cloud ...
Amazon started as an online bookseller 20 years ago. Since then, it has evolved into a technology juggernaut that has disrupted multiple markets and industries and touches many aspects of our lives. It is a relentless technology and business model innovator driving disruption throughout numerous ecosystems. Amazon’s AWS revenues alone are approaching $16B a year making it one of the largest IT companies in the world. With dominant offerings in Cloud, IoT, eCommerce, Big Data, AI, Digital Assista...
Artificial intelligence, machine learning, neural networks. We’re in the midst of a wave of excitement around AI such as hasn’t been seen for a few decades. But those previous periods of inflated expectations led to troughs of disappointment. Will this time be different? Most likely. Applications of AI such as predictive analytics are already decreasing costs and improving reliability of industrial machinery. Furthermore, the funding and research going into AI now comes from a wide range of com...
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business - from apparel to energy - is being rewritten by software. From planning to development to management to security, CA creates software that fuels transformation for companies in the applic...
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists looked at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deliver...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
SYS-CON Events announced today that Cloud Academy named "Bronze Sponsor" of 21st International Cloud Expo which will take place October 31 - November 2, 2017 at the Santa Clara Convention Center in Santa Clara, CA. Cloud Academy is the industry’s most innovative, vendor-neutral cloud technology training platform. Cloud Academy provides continuous learning solutions for individuals and enterprise teams for Amazon Web Services, Microsoft Azure, Google Cloud Platform, and the most popular cloud com...
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
21st International Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Me...
@DevOpsSummit at Cloud Expo taking place Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center, Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is ...
SYS-CON Events announced today that Enzu will exhibit at SYS-CON's 21st Int\ernational Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive advantage. By offering a suite of proven hosting and management services, Enzu wants companies to focus on the core of their ...
"We are a monitoring company. We work with Salesforce, BBC, and quite a few other big logos. We basically provide monitoring for them, structure for their cloud services and we fit into the DevOps world" explained David Gildeh, Co-founder and CEO of Outlyer, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
We build IoT infrastructure products - when you have to integrate different devices, different systems and cloud you have to build an application to do that but we eliminate the need to build an application. Our products can integrate any device, any system, any cloud regardless of protocol," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA